During the past decade, Studienzentrum für Neurologie und Psychiatrie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Studienzentrum für Neurologie und Psychiatrie" are "Multiple Sclerosis, Relapsing-Remitting" (2 trials), "Multiple Sclerosis, Primary Progressive" (1 trials), "Relapsing Multiple Sclerosis" (1 trials) and "Schizophrenia" (1 trials). Many other conditions were trialed in "Studienzentrum für Neurologie und Psychiatrie" in a lesser frequency.

Most popular intervention types in "Studienzentrum für Neurologie und Psychiatrie" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (3 trials), "Fenebrutinib" (2 trials), "Placebo" (2 trials), "Iclepertin" (1 trials) and "Placebo matched to fenebrutinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Studienzentrum für Neurologie und Psychiatrie" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Studienzentrum für Neurologie und Psychiatrie". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Studienzentrum für Neurologie und Psychiatrie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Studienzentrum für Neurologie und Psychiatrie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".